Key Performance
More- Earnings Score: 41
- Momentum Score: 9
- True Yield: N/A
- Financial Health Score: 9
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Robbins LLP is investigating Simulation Plus, Inc. (NASDAQ: SLP) for potential securities law violations and breach of fiduciary duties. The investigation follows significant stock declines triggered by disappointing revenue guidance in June 2025 (24% drop) and poor Q3 fiscal 2025 results including a $67.3 million net loss and $77.2 million impairment charge in July 2025 (26% drop). The company subsequently dismissed its auditor, Grant Thornton LLP, citing unresolved issues with segment reporting and internal controls.
06/02/2026, 7:18 PM • GlobeNewswire
Global Biosimulation Market Poised for Phenomenal Expansion at a CAGR of ~17% by 2034 | DelveInsight
The biosimulation market is experiencing robust growth, projected to expand from USD 4.7 billion in 2025 to USD 20 billion by 2034 at a CAGR of ~17%. Growth is driven by increasing adoption of model-informed drug development (MIDD), rising complexity of modern therapeutics, regulatory support from FDA and EMA, and the shift toward virtual clinical trials and precision medicine. North America leads the market with 44.24% share, while Asia-Pacific emerges as a major growth contributor.
04/27/2026, 1:00 PM • GlobeNewswire
Certara Strategic Business Divestiture Comes At Right Time, Says Analyst
Certara announced the sale of its Regulatory and Medical Writing business to Veristat for up to $135 million. The divestiture is expected to close in Q2 2026 and will allow the company to focus on its Model-Informed Drug Development platform. Analysts view this as strategically positive timing, with William Blair noting it removes an overhang and provides capital for reinvestment in core biosimulation platforms.
04/22/2026, 3:23 PM • Benzinga
U.S. stock futures fell on Friday amid Middle East tensions over Iran-Israel ceasefire violations and ahead of March CPI data release. Major indices traded lower with the Dow, S&P 500, and Nasdaq 100 all declining slightly. Crude oil surged 2.31% to $100.13/barrel due to geopolitical concerns. Key gainers included Taiwan Semiconductor (up 1.81% on strong Q1 revenue), Simulations Plus (up 13.24% on better-than-expected results), and Urban-gro (up 12.31% on new strategy). Analysts remain cautiously optimistic about 2026 earnings growth despite headwinds from energy shocks and inflation.
04/10/2026, 8:46 AM • Benzinga
U.S. stock futures fell on Friday amid Middle East tensions over Iran-Israel ceasefire violations and ahead of March CPI data release. Major indices traded lower with the Dow, S&P 500, and Nasdaq 100 all declining slightly. Crude oil surged 2.31% to $100.13/barrel due to geopolitical concerns. Key gainers included Taiwan Semiconductor (up 1.81% on strong Q1 revenue), Simulations Plus (up 13.24% on better-than-expected results), and Urban-gro (up 12.31% on new strategy announcement).
04/10/2026, 5:13 AM • Benzinga
The Rosen Law Firm is investigating potential securities claims against Simulations Plus, Inc. (NASDAQ: SLP) for allegedly issuing materially misleading business information. The company missed earnings expectations in Q3 2025, reporting $20.4 million in sales versus a consensus estimate of $20.9 million, causing the stock to plummet 25.75% on July 15, 2025. The firm is preparing a class action lawsuit to recover investor losses.
02/10/2026, 2:37 PM • GlobeNewswire
The Rosen Law Firm is investigating potential securities claims against Simulations Plus, Inc. (NASDAQ: SLP) for allegedly issuing materially misleading business information. The company missed earnings expectations in Q3 2025, reporting $20.4 million in sales versus a consensus estimate of $20.9 million, causing the stock to plummet 25.75% on July 15, 2025. Investors who suffered losses are encouraged to join a prospective class action lawsuit.
02/05/2026, 7:40 PM • GlobeNewswire
The Rosen Law Firm is investigating potential securities claims against Simulations Plus, Inc. (NASDAQ: SLP) for allegedly issuing materially misleading business information. The company's stock fell 25.75% on July 15, 2025, following the release of third-quarter 2025 earnings that missed consensus estimates, with sales of $20.4 million versus expected $20.9 million. Investors who suffered losses are encouraged to join a prospective class action lawsuit.
02/02/2026, 7:12 PM • GlobeNewswire
Rosen Law Firm is investigating potential securities claims against Simulations Plus, Inc. (NASDAQ: SLP) for allegedly issuing materially misleading business information. The company missed earnings expectations in Q3 2025, reporting $20.4 million in sales versus a consensus estimate of $20.9 million, causing the stock to plummet 25.75% on July 15, 2025. Investors who suffered losses are encouraged to join a prospective class action lawsuit.
01/30/2026, 5:00 PM • GlobeNewswire
The Rosen Law Firm is investigating potential securities claims on behalf of Simulations Plus shareholders. The company missed Q3 2025 earnings expectations with $20.4 million in sales versus a $20.9 million consensus estimate, causing the stock to plunge 25.75% on July 15, 2025. Investors who suffered losses are encouraged to join a prospective class action lawsuit.
01/27/2026, 6:49 PM • GlobeNewswire
The Rosen Law Firm has announced investigations into potential securities claims against Trip.com Group Limited following a 17% stock decline after Chinese regulators launched an antitrust probe. The firm is also investigating claims against CoreWeave, Inc. and Simulations Plus, Inc., offering contingency-based representation for affected shareholders.
01/20/2026, 5:27 PM • GlobeNewswire
The Rosen Law Firm is investigating potential securities claims on behalf of Simulations Plus shareholders, alleging the company issued materially misleading business information. Simulations Plus reported Q3 2025 sales of $20.4 million, missing consensus estimates of $20.9 million, causing the stock to plummet 25.75% on July 15, 2025. The firm is preparing a class action lawsuit to recover investor losses.
01/20/2026, 2:34 PM • GlobeNewswire
Why Shares of Simulations Plus Soared This Week
Simulations Plus reported mixed Q4 results with a 6% revenue decline, but provided optimistic fiscal 2026 guidance projecting 0-4% revenue growth and potential AI-driven solutions, leading to a 21.6% stock price increase.
12/04/2025, 12:30 PM • The Motley Fool
Simulations Plus reported a significant quarterly loss of $67.3 million, missed sales estimates, and initiated a restructuring, causing its stock price to drop 25.76%.
11/01/2025, 10:53 AM • GlobeNewswire
Rosen Law Firm is investigating potential securities claims against Simulations Plus after the company reported Q3 2025 earnings that missed consensus estimates, causing a 25.75% stock price decline.
10/27/2025, 5:00 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/03/2026
Company Profile
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, and Thales products. In addition, the company offers Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, it provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, the company offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Research Triangle Park, North Carolina.